P‐glycoprotein Influences the Brain Concentrations of Cetirizine (Zyrtec®), a Second‐Generation Non‐Sedating Antihistamine
- 1 October 2003
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 92 (10) , 2082-2089
- https://doi.org/10.1002/jps.10453
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Role of P-Glycoprotein in PharmacokineticsClinical Pharmacokinetics, 2003
- Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discoveryBiopharmaceutics & Drug Disposition, 2002
- The superfamily of organic anion transporting polypeptidesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2002
- Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed DrugsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drugExpert Opinion on Investigational Drugs, 2001
- Affinity for the P-Glycoprotein Efflux Pump at the Blood-Brain Barrier May Explain the Lack of CNS Side-Effects of Modern AntihistaminesJournal of Drug Targeting, 2001
- Why are non-sedating antihistamines non-sedating?Clinical and Experimental Allergy, 1999
- Therapeutic advantages of third generation antihistaminesExpert Opinion on Investigational Drugs, 1998
- The Pharmacology and Use of H1-Receptor-Antagonist DrugsNew England Journal of Medicine, 1994
- Cetirizine: Actions on neurotransmitter receptorsJournal of Allergy and Clinical Immunology, 1990